Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: A systematic review

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Cimo, Adriana ^a   Stergiopoulos, Erene ^a   Cheng, Chiachen ^a,b   Bonato, Sarah ^a   Dewa, Carolyn S ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b CANADIAN MENTAL HEALTH ASSOCIATION   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; NEUROLEPTIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; COGNITION; DIABETES EDUCATION; DIET THERAPY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION EDUCATION; SCHIZOAFFECTIVE PSYCHOSIS; SELF CARE; SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION; DIET; LIFESTYLE; METHODOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; AWARENESS; BODY MASS; DIABETES CONTROL; DIABETIC PATIENT; GLYCEMIC CONTROL; MENTAL DISEASE; OUTCOMES RESEARCH; OUTPATIENT CARE; PHYSICAL ACTIVITY; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION CARE; WEIGHT CHANGE;

DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; LIFE STYLE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SELF CARE;

EID: 84858711151     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-24     Document Type: Article

References (42)

1. World Health Organization Diabetes Fact sheet N°312. World Health Organization., http://www.who.int/mediacentre/factsheets/fs312/en/
2. World Health Organization 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. World Health Organization., http://www.who.int/nmh/Actionplan-PC-NCD-2008.pdf
3. Nelms M, Sucher KP, Lacey K, Long Roth S. Nutrition Therapy and Pathophysiology 2010, Belmont, CA: Wadsworth Cengage Learning, 2.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity.
5. Heald A. Physical health in schizophrenia: a challenge for antipsychotic therapy. Eur Psychiatry 2010, 25:S6-S11.
6. El-Mallakh P. Doing my best: Poverty and self-care among individuals with schizophrenia and diabetes mellitus. Arch Psychiatr Nurs 2007, 21:49-60. 10.1016/j.apnu.2006.10.004, 17258110.
7. Gough SCL, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J Psychopharmacol 2005, 19:47-55. 10.1177/0269881105058380, 16280337.
8. Krosnick A, Wilson MG. A retrospective chart review of the clinical effects of atypical antipsychotic drugs on glycemic control in institutionalized patients with schizophrenia and comorbid diabetes mellitus. Clin Ther 2005, 27:320-326. 10.1016/j.clinthera.2005.02.017, 15878385.
9. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics - Literature review and clinical implications. Drugs 2004, 64:701-723. 10.2165/00003495-200464070-00003, 15025545.
10. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007, 21:357-373.
11. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry-Revue Canadienne De Psychiatrie 2006, 51:492-501.
12. Woo V, Harris SB, Houlden RL. Canadian Diabetes Association Position Paper: Antipsychotic Medications and Associated Risks of Weight Gain and Diabetes. Can J Diabetes 2005, 29:111-112.
13. Canadian Diabetes Association Clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008, 32(Supplement 1):S1-S201. Canadian Diabetes Association.
14. American Diabetes Association Standards of medical care in diabetes - 2012. Diabetes Care 2012, 35(Sup):S11-S63. American Diabetes Association.
15. Goldberg RW, Kreyenbuhl JA, Medoff DR, Dickerson FB, Wohlheiter K, Fang J, Brown CH, Dixon LB. Quality of diabetes care among adults with serious mental illness. Psychiatr Serv 2007, 58:536-543. 10.1176/appi.ps.58.4.536, 17412857.
16. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, Sharkansky EJ, Keane TM, Skinner KM, Rosen CS, Berlowitz DR. Disparities in Diabetes Care. Arch Intern Med 2005, 165:2631-2638. 10.1001/archinte.165.22.2631, 16344421.
17. Dickerson FB, Goldberg RW, Brown CH, Kreyenbuhl JA, Wohlheiter K, Fang L, Medoff D, Dixon LB. Diabetes knowledge among persons with serious mental illness and type 2 diabetes. Psychosomatics 2005, 46:418-424. 10.1176/appi.psy.46.5.418, 16145186.
18. Becker T, Hux J. Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care 2011, 34:398-402. 10.2337/dc10-1139, 3024356, 20978096.
19. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can j psychiatry Revue canadienne de psychiatrie 1991, 36:239-245.
20. Lagerveld SE, Bultmann U, Franche RL, van Dijk FJ, Vlasveld MC, van der Feltz-Cornelis CM, Bruinvels DJ, Huijs JJ, Blonk RW, van der Klink JJ, Nieuwenhuijsen K. Factors associated with work participation and work functioning in depressed workers: a systematic review. J Occup Rehabil 2010, 20:275-292. 10.1007/s10926-009-9224-x, 2923705, 20091105.
21. Mallen C, Peat G, Croft P. Quality assessment of observational studies is not commonplace in systematic reviews. J Clin Epidemiol 2006, 59:765-769. 10.1016/j.jclinepi.2005.12.010, 16828667.
22. Dickinson D, Gold JM, Dickerson FB, Medoff D, Dixon LB. Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 2008, 49:123-131. 10.1176/appi.psy.49.2.123, 18354065.
23. McKibbin CL, Patterson TL, Norman G, Patrick K, Jin H, Roesch S, Mudaliar S, Barrio C, O'Hanlon K, Griver K, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. Schizophr Res 2006, 86:36-44. 10.1016/j.schres.2006.05.010, 16842977.
24. Lindenmayer JP, Khan A, Wance D, Maccabee N, Kaushik S. Outcome Evaluation of a Structured Educational Wellness Program in Patients With Severe Mental Illness. J Clin Psychiatry 2009, 70:1385-1396. 10.4088/JCP.08m04740yel, 19778494.
25. Teachout A, Kaiser SM, Wilkniss SM, Moore H. Paxton House: Integrating Mental Health and Diabetes Care for People with Serious Mental Illnesses in a Residential Setting. Psychiatric Rehabil J 2011, 34:324-327.
26. McKibbin CL, Golshan S, Griver K, Kitchen K, Wykes TL. A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: A 6-month follow-up analysis. Schizophr Res 2010, 121:203-206. 10.1016/j.schres.2009.09.039, 20434886.
27. Lerner V, Libov I, Kanevsky M. High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients. Int J Psychiatry Med 2003, 33:403-410. 10.2190/8J17-J4PB-F2KX-05YY, 15152791.
28. Wu P-L, Lane H-Y, Su K-P. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus. Psychiatry Clin Neurosci 2006, 60:115-116. 10.1111/j.1440-1819.2006.01469.x, 16472369.
29. Melkersson K, Hulting A-L. Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine. Psychosomatics: J Consult Liaison Psychiatry 2002, 43:67-70.
30. Waldman JC, Yaren S. Atypical antipsychotics and glycemia: a case report. The Can J Psychiatry/La Revue canadienne de psychiatrie 2002, 47:686-687.
31. Ashim S, Warrington S, Anderson IM. Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications. J Psychopharmacol 2004, 18:128-132. 10.1177/0269881104040253, 15107197.
32. Gothefors D, Adolfsson R, Attvall S, Erlinge D, Jarbin H, Lindstrom K, von Hausswolff-Juhlin YL, Morgell R, Toft E, Osby U. Swedish clinical guidelines-Prevention and management of metabolic risk in patients with severe psychiatric disorders. Nordic J Psychiatry 2010, 64:294-302.
33. Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. Bmc Med 2008, 6:17. 10.1186/1741-7015-6-17, 2474645, 18590519.
34. Weiden PJ. Switching in the era of atypical antipsychotics. An updated review. Postgrad Med 2006, Spec No:27-44.
35. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993, 19:287-302.
36. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing Atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004, 65:471-477.
37. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161. 10.2337/diacare.27.1.155, 14693982.
38. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011,
39. Landgraf R. HbA1c-the gold standard in the assessment of diabetes treatment?. Dtsch Med Wochenschr 2006, 131(Suppl 8):S243-246.
40. Ariens GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G. Physical risk factors for neck pain. Scand J Work Environ Health 2000, 26:7-19. 10.5271/sjweh.504, 10744172.
41. American Diabetes Association Diabetes Statistics. American Diabetes Association., http://www.diabetes.org/diabetes- basics/diabetes-statistics/
42. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007, 369:750-756. 10.1016/S0140-6736(07)60361-4, 17336651.